BusinessIndustries

Cancer Diagnostics Market Worth US Dollar 250.3 Billion by 2026 | CAGR: 7.2% Between 2018 to 2026

A new research report is published by Acumen Research and Consulting on "Cancer Diagnostics Market" Industry Size, Share, Trends and Forecast 2026

International cancer diagnostics industry size is expected to worth around USD 250.3 billion by 2026. The market is predictable to showcase a CAGR of 7.2% during the forthcoming years.

Persistent introduction of innovative and advance products, combined with expanding requirement for early detection of different infections and diseases, is a prime factor driving the market. Likewise, fast development of the healthcare and diagnostics sector segment can be credited to entrance of innovatively propelled research facility system that have enhanced oncological screening in yielding exact results. Rising occurrence of malignant growth is activating demand for these screening tests and imaging modalities utilized for checking illness movement.

Collaborative and independent activities driven by governments and organizations are endeavouring to raise awareness about the advantages of early malignant growth detection. Also, cancer research organizations, alongside public and private elements, are contributing vigorously on research undertakings to launch progressed analytic or diagnostic devices in the market, which are fit for diagnosing the ailment much before the symptoms appear.

Request a Sample Copy of Cancer Diagnostics [email protected] https://www.acumenresearchandconsulting.com/request-sample/1144

Moreover, giant players are working together with governments and different organizations to upgrade understanding availability to these tests and products. For example, Illumina, Inc. propelled another endeavour called GRAIL with financial specialists, Jeff Bezos and Bill Gates, with a venture of more than USD 100 million. GRAIL is for the most part focused on blood-based oncological screening for auspicious analysis of the most widely recognized tumour types through laboratory tests.

The breast cancer growth portion caught the biggest offer of 15.0% in 2018 in the disease diagnostics market. Mammography is the most well-known and prevalent screening test utilized for breast tumour screening. As per the United States Preventive Services Task Force (USPSTF), ladies aged somewhere in the range of 50 and 74 years are at a higher danger of creating breast malignant growth. Along these lines, USPSTF prescribes ladies over 40 years old to experience mammography every two years.

Also, numerous associations, for example, the National Breast Cancer Foundation, Inc. are embraced activities to spread mindfulness in regards to breast cancer growth, advantages of early location, and accessible treatment alternatives. Increasing cognizance of the populace, combined with campaigns promoting routine mammography, is bringing about extreme demand for imaging arrangements in breast disease screening.

The global cancer diagnostics market is segmented into type, application and region. On the basis type, the global Cancer diagnostics market is segmented into Laboratory Tests, Genetic Tests, Imaging, Endoscopy, Biopsy, and Others (barium enema). On the basis application, the global Cancer diagnostics market is segmented into Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer, Skin Cancer, Blood Cancer, Kidney Cancer, Liver Cancer, Pancreatic Cancer, Ovarian Cancer, and Others. On the basis of region the global Cancer diagnostics market is bifurcated into North America, Latin America, Europe, Middle East & Africa, and Asia Pacific.

Browse Full Report with Table of Content, List of Table and [email protected] https://www.acumenresearchandconsulting.com/cancer-diagnostics-market

North America ruled the industry by capturing the biggest revenue share offer of 43.0% in 2018. Nearness of various biotechnology just as medicinal gadget organizations in the locale is one of the prime elements driving the diagnostics sector in the region. North America is relied upon to proceed with its lead all through the estimate time frame inferable from elements, for example, more prominent subsidizing accessible for research and development projects and high reception of cutting edge innovations. Asia Pacific is relied upon to show the most astounding development sooner rather than later because of quality of a substantial patient pool, accessibility of skilled experts at a relatively lower cost, and a characterized administrative structure favouring expedited product approvals. Besides, the blasting tourism the travel industry in nations, for example, India, China, and Malaysia are relied upon to help demand for oncological screening.

Moreover, positive government strategies supporting the development of the manufacturing business, combined with lower manufacturing costs in nations, for example, India and China, are required to pull in the consideration of worldwide players to set up their production plants in these nations. Likewise, the normal ascent in patient base in Asia Pacific is foreseen to support market development sooner rather than later.

The major enterprises working in the global cancer diagnostics market are Hologic, Inc.; GE Healthcare; Koninklijke Philips N.V.; Abbott; Illumina, Inc.; Hoffmann-La Roche Ltd.; Becton Dickinson & Company; and Siemens Healthcare GmbH.

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Cancer Diagnostics
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Cancer Diagnostics Market By Type
1.2.2.1. Global Cancer Diagnostics Market Revenue and Growth Rate Comparison By Type (2015-2026)
1.2.2.2. Global Cancer Diagnostics Market Revenue Share By Type in 2017
1.2.2.3. Laboratory Tests
1.2.2.4. Genetic Tests
1.2.2.5. Imaging
1.2.2.6. Endoscopy
1.2.2.7. Biopsy
1.2.2.8. Others (barium enema)
1.2.3. Cancer Diagnostics Market By Application
1.2.3.1. Global Cancer Diagnostics Market Revenue and Growth Rate Comparison By Application (2015-2026)
1.2.3.2. Global Cancer Diagnostics Market Revenue Share By Application in 2017
1.2.3.3. Breast Cancer
1.2.3.4. Colorectal Cancer
1.2.3.5. Cervical Cancer
1.2.3.6. Lung Cancer
1.2.3.7. Prostate Cancer
1.2.3.8. Skin Cancer
1.2.3.9. Blood Cancer
1.2.3.10. Kidney Cancer
1.2.3.11. Liver Cancer
1.2.3.12. Pancreatic Cancer
1.2.3.13. Ovarian Cancer
1.2.3.14. Others
1.2.4. Cancer Diagnostics Market by Geography
1.2.4.1. Global Cancer Diagnostics Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.4.2. North America Cancer Diagnostics Market Revenue and Growth Rate (2015-2026)
1.2.4.3. Europe Cancer Diagnostics Market Revenue and Growth Rate (2015-2026)
1.2.4.4. Asia-Pacific Cancer Diagnostics Market Revenue and Growth Rate (2015-2026)
1.2.4.5. Latin America Cancer Diagnostics Market Revenue and Growth Rate (2015-2026)
1.2.4.6. Middle East and Africa (MEA) Cancer Diagnostics Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Cancer Diagnostics Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Cancer Diagnostics Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Cancer Diagnostics Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Cancer Diagnostics Major Manufacturers in 2017

CHAPTER 4. CANCER DIAGNOSTICS MARKET BY TYPE

4.1. Global Cancer Diagnostics Revenue By Type
4.2. Laboratory Tests
4.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.3. Genetic Tests
4.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.4. Imaging
4.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.5. Endoscopy
4.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.6. Biopsy
4.6.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.7. Others (barium enema)
4.7.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.7.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 5. CANCER DIAGNOSTICS MARKET BY APPLICATION

5.1. Global Cancer Diagnostics Revenue By Application
5.2. Breast Cancer
5.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.3. Colorectal Cancer
5.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.4. Cervical Cancer
5.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.5. Lung Cancer
5.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.6. Prostate Cancer
5.6.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.6.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.7. Skin Cancer
5.7.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.7.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.8. Blood Cancer
5.8.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.8.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.9. Kidney Cancer
5.9.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.9.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.10. Liver Cancer
5.10.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.10.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.11. Pancreatic Cancer
5.11.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.11.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.12. Ovarian Cancer
5.12.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.12.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.13. Others
5.13.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.13.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 6. NORTH AMERICA CANCER DIAGNOSTICS MARKET BY COUNTRY

6.1. North America Cancer Diagnostics Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.2. North America Cancer Diagnostics Market Revenue Share Comparison, 2015 & 2026 (%)
6.3. U.S.
6.3.1. U.S. Cancer Diagnostics Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
6.3.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
6.4. Canada
6.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
6.4.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
6.5. Mexico
6.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
6.5.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)

CHAPTER 7. EUROPE CANCER DIAGNOSTICS MARKET BY COUNTRY

7.1. Europe Cancer Diagnostics Market Revenue and Growth Rate, 2015 – 2026 ($Million)
7.2. Europe Cancer Diagnostics Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. UK
7.3.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
7.3.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
7.4. Germany
7.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
7.4.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
7.5. France
7.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
7.5.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
7.6. Spain
7.6.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
7.6.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
7.7. Rest of Europe
7.7.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
7.7.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)

CHAPTER 8. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET BY COUNTRY

8.1. Asia-Pacific Cancer Diagnostics Market Revenue and Growth Rate, 2015 – 2026 ($Million)
8.2. Asia-Pacific Cancer Diagnostics Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. China
8.3.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
8.3.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
8.4. Japan
8.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
8.4.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
8.5. India
8.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
8.5.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
8.6. Australia
8.6.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
8.6.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
8.7. South Korea
8.7.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
8.7.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
8.8. Rest of Asia-Pacific
8.8.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
8.8.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)

CHAPTER 9. LATIN AMERICA CANCER DIAGNOSTICS MARKET BY COUNTRY 

9.1. Latin America Cancer Diagnostics Market Revenue and Growth Rate, 2015 – 2026 ($Million)
9.2. Latin America Cancer Diagnostics Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. Brazil
9.3.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.3.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
9.4. Argentina
9.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.4.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
9.5. Rest of Latin America
9.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.5.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)

CHAPTER 10. MIDDLE EAST CANCER DIAGNOSTICS MARKET BY COUNTRY 

10.1. Middle East Cancer Diagnostics Market Revenue and Growth Rate, 2015 – 2026 ($Million)
10.2. Middle East Cancer Diagnostics Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Saudi Arabia
10.3.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.3.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
10.4. UAE
10.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.4.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
10.5. Rest of Middle East
10.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.5.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)

CHAPTER 11. AFRICA CANCER DIAGNOSTICS MARKET BY COUNTRY 

11.1. Africa Cancer Diagnostics Market Revenue and Growth Rate, 2015 – 2026 ($Million)
11.2. Africa Cancer Diagnostics Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. South Africa
11.3.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
11.3.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
11.4. Egypt
11.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
11.4.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)
11.5. Rest of Africa
11.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
11.5.2. Market Revenue and Forecast By Application, 2015 – 2026 ($Million)

CHAPTER 12. COMPANY PROFILE

12.1. Hologic, Inc.
12.1.1. Company Snapshot
12.1.2. Overview
12.1.3. Financial Overview
12.1.4. Product Portfolio
12.1.5. Key Developments
12.1.6. Strategies
12.2. GE Healthcare
12.2.1. Company Snapshot
12.2.2. Overview
12.2.3. Financial Overview
12.2.4. Product Portfolio
12.2.5. Key Developments
12.2.6. Strategies
12.3. Koninklijke Philips N.V.
12.3.1. Company Snapshot
12.3.2. Overview
12.3.3. Financial Overview
12.3.4. Product Portfolio
12.3.5. Key Developments
12.3.6. Strategies
12.4. Abbott
12.4.1. Company Snapshot
12.4.2. Overview
12.4.3. Financial Overview
12.4.4. Product Portfolio
12.4.5. Key Developments
12.4.6. Strategies
12.5. Illumina, Inc.
12.5.1. Company Snapshot
12.5.2. Overview
12.5.3. Financial Overview
12.5.4. Product Portfolio
12.5.5. Key Developments
12.5.6. Strategies
12.6. Hoffmann-La Roche Ltd.
12.6.1. Company Snapshot
12.6.2. Overview
12.6.3. Financial Overview
12.6.4. Product Portfolio
12.6.5. Key Developments
12.6.6. Strategies
12.7. Becton Dickinson & Company
12.7.1. Company Snapshot
12.7.2. Overview
12.7.3. Financial Overview
12.7.4. Product Portfolio
12.7.5. Key Developments
12.7.6. Strategies
12.8. Siemens Healthcare GmbH
12.8.1. Company Snapshot
12.8.2. Overview
12.8.3. Financial Overview
12.8.4. Product Portfolio
12.8.5. Key Developments
12.8.6. Strategies
12.9. Others
12.9.1. Company Snapshot
12.9.2. Overview
12.9.3. Financial Overview
12.9.4. Product Portfolio
12.9.5. Key Developments
12.9.6. Strategies

CHAPTER 13. RESEARCH APPROACH

13.1. Research Methodology
13.1.1. Initial Data Search
13.1.2. Secondary Research
13.1.3. Primary Research
13.2. Assumptions and Scope

To Purchase this Premium [email protected] https://www.acumenresearchandconsulting.com/buy-now/0/1144

The report is readily available and can be dispatched immediately after payment confirmation.

Would like to place an order or any question, please feel free to contact at [email protected] | +1 407 915 4157

Tags

Related Articles

Close